| 2025 | 2024 | 2023 | 2022 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | -597,5 k € | -12095.6% | -4,9 k € | -89.5% | -2,6 k € | — | -68,9 € | +97.1% | -2,4 k € | +14.4% | -2,8 k € | -665.2% | -368,0 € | -103.8% | -180,6 € | +97.3% | -6,6 k € | +21.2% | -8,4 k € | -1.1% | -8,3 k € | -195.1% | -2,8 k € | +8.6% | -3,1 k € | +84.5% | -20,0 k € | -106.6% | 300,2 k € | |||
| EBITDA | -1,1 M € | -22448.4% | -4,9 k € | -65.0% | -3,0 k € | -754.6% | -347,5 € | +49.3% | -685,6 € | +77.1% | -3,0 k € | +5.5% | -3,2 k € | -479.4% | -546,0 € | -3.4% | -528,1 € | +92.5% | -7,1 k € | +20.2% | -8,9 k € | +5.0% | -9,3 k € | -220.4% | -2,9 k € | +8.3% | -3,2 k € | +76.4% | -13,5 k € | -105.0% | 270,7 k € | |
| Operating profit | -1,4 M € | -27657.0% | -4,9 k € | -65.0% | -3,0 k € | -754.6% | -347,5 € | +49.3% | -685,6 € | +77.1% | -3,0 k € | +5.5% | -3,2 k € | -479.4% | -546,0 € | -3.4% | -528,1 € | +92.5% | -7,1 k € | +20.2% | -8,9 k € | +5.0% | -9,3 k € | -220.4% | -2,9 k € | +8.3% | -3,2 k € | +76.4% | -13,5 k € | -105.0% | 270,7 k € | |
| Profit/loss | -1,4 M € | -26940.9% | -5,0 k € | -65.0% | -3,0 k € | -553.8% | -466,2 € | +31.9% | -685,0 € | +77.1% | -3,0 k € | +5.5% | -3,2 k € | -467.2% | -557,6 € | -128.1% | 2,0 k € | +128.1% | -7,1 k € | +67.5% | -21,7 k € | -136.6% | -9,2 k € | -246.2% | -2,7 k € | -183.2% | -936,0 € | +87.3% | -7,4 k € | -102.3% | 315,1 k € | |
| Equity | -441,9 k € | -164.0% | 690,5 k € | +7832.6% | 8,7 k € | -25.9% | 11,8 k € | -14.5% | 13,7 k € | -4.7% | 14,4 k € | -17.2% | 17,4 k € | -15.4% | 20,6 k € | -2.6% | 21,1 k € | +10.3% | 19,2 k € | -26.9% | 26,2 k € | -45.3% | 47,9 k € | -16.1% | 57,1 k € | -4.4% | 59,7 k € | -1.5% | 60,7 k € | -10.8% | 68,0 k € | |
| Total assets | 1,5 M € | +121.0% | 690,7 k € | +7835.1% | 8,7 k € | -28.1% | 12,1 k € | -15.3% | 14,3 k € | -1.0% | 14,4 k € | -17.2% | 17,4 k € | -15.3% | 20,6 k € | -4.9% | 21,6 k € | -3.0% | 22,3 k € | -30.1% | 31,9 k € | -37.8% | 51,3 k € | -12.2% | 58,4 k € | -9.4% | 64,5 k € | -4.2% | 67,4 k € | -90.6% | 713,5 k € | |
| Cash | 521,4 k € | -24.5% | 690,7 k € | +19278.9% | 3,6 k € | -70.5% | 12,1 k € | -14.9% | 14,2 k € | -1.0% | 14,4 k € | -15.0% | 16,9 k € | -17.6% | 20,5 k € | +163.5% | 7,8 k € | -7.8% | 8,4 k € | +39.2% | 6,1 k € | +524.2% | 971,8 € | -73.0% | 3,6 k € | +489.5% | 610,0 € | -94.8% | 11,7 k € | +230.3% | 3,5 k € | |
| Debts | 2,0 M € | +929571.2% | 211,8 € | 0,0 € | -100.0% | 347,5 € | -35.8% | 541,6 € | — | — | — | 501,1 € | -84.0% | 3,1 k € | -44.7% | 5,7 k € | +67.4% | 3,4 k € | +150.5% | 1,4 k € | -71.6% | 4,8 k € | -15.4% | 5,6 k € | -99.1% | 638,6 k € | ||||||
Public limited company · Ottignies-Louvain-la-Neuve · incorporated on 13/10/2004
Public limited company loss-making in the latest fiscal year. Cash position declining (-24.5%).
Acceptable counterparty for a moderate engagement. Require 2 fiscal years of detailed accounts before any significant exposure. The abridged model hides revenue.
ChemoSensoryX Biosciences SA is a Public limited company incorporated in 2004. Its main activity is: Research and experimental development on natural sciences and engineering. Its registered office is in Ottignies-Louvain-la-Neuve.
Key indicators
7-day free trial, no credit card required.
7-day free trial, no credit card required.
7-day free trial, no credit card required.
Source: Belgian Official Gazette